このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Observation on the Efficacy of Aflibercept 8mg Intravitreal Injection Solution on Retinal Fluid in nAMD Patients With PED (Fluid-8)

2026年11月16日 更新者:Honghua Yu,MD

Observation on the Efficacy of Aflibercept 8mg Intravitreal Injection Solution on Retinal Fluid in nAMD Patients With PED: a Multicenter, Prospective Study

Primary Objective: To describe the changes in macular fluid within 12 months in patients with neovascular agerelated macular degeneration (nAMD) complicated by pigment epithelial detachment (PED) receiving 8mg aflibercept treatandextend (T&E) therapy.Secondary Objectives:(1) To explore the correlation between changes in macular fluid (e.g., fluctuation index [FI], volume change, etc.) and visual acuity improvement;(2) To evaluate the associations of macular fluid changes (e.g., fluctuation index [FI], volume change, etc.) and different types of fluid components with alterations in retinal and choroidal structures (e.g., disruption of the ellipsoid zone, thickness of each retinal layer, choroidal thickness, microstructural parameters on OCT and OCTA, etc.);(3) To assess the safety of 8mg aflibercept injections in nAMD patients with PED (e.g., incidence rates of retinal pigment epithelium (RPE) tear, elevated intraocular pressure, endophthalmitis and thromboembolic events).

  1. Study Design (1) Type: Prospective, single-arm, open-label, multicenter study. (2) Sample size: The sample size was calculated based on the Fluid Index (FI) with reference to the results of the TOWER study. The TOWER study described the 24-month macular fluid fluctuation after intravitreal anti-VEGF therapy (bevacizumab, ranibizumab and 2 mg aflibercept) for nAMD in the real-world setting. This study hypothesizes that 8 mg aflibercept is non-inferior to the above three agents in controlling fluid fluctuation. Based on the TOWER study, the assumed mean FI at Month 12 is 42.9 with an SD of 9.8; a sample size of 38 yields a two-sided 95% confidence interval with a half-width of 3.22. Assuming a 20% dropout rate, the minimum number of patients required to reach the primary endpoint is 48. (3) Rationale for indication: The study population consists of patients with nAMD, for which aflibercept is a first-line treatment. The intervention is intravitreal injection of 8 mg aflibercept, whose efficacy and safety have been demonstrated in previous Phase III clinical trials. The T&E regimen is a globally recognized optimized treatment strategy that reduces the treatment burden on patients and healthcare facilities while maintaining sustained disease control.
  2. Study Procedures This study includes a 3-week screening period to assess subject eligibility, followed by a 48-week treatment period. Subjects who provide consent, meet all inclusion criteria and do not meet any exclusion criteria will receive intravitreal injection of 8 mg aflibercept in the study eye. Referencing the ALTAIR study, this study adopts the T&E (treat-and-extend) regimen: one intravitreal injection is administered at Week 0, Week 4 and Week 8 during the loading phase, and the maintenance phase starts at Week 20. During the maintenance phase, all decisions to extend, maintain or shorten the dosing interval are made according to the T&E criteria. The treatment interval should be shortened if any of the following occurs: new fluid (across all tomographic scans), no improvement or worsening of pre-existing fluid, a loss of ≥5 letters in visual acuity compared with the last visit, an increase of ≥100 μm in CRT in the central 1 mm subfield relative to the previous minimum value, or new neovascularization / new submacular hemorrhage. If the criteria for interval shortening are not met, the current interval will be maintained if fluid persists but shows a continuous decreasing trend; the injection interval may be extended as appropriate if there is no active fluid on OCT. In principle, the injection interval is adjusted within the range of 8-24 weeks, with a default adjustment step of 4 weeks each time.

調査の概要

状態

まだ募集していません

介入・治療

研究の種類

介入

入学 (推定)

48

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

50年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • 1: (1) Age ≥ 50 years old;

    2: (2) Patients with newlydiagnosed or preexisting nAMD and OCTconfirmed PED;

    3: (3) Patients who are planned to initiate intravitreal injection of aflibercept 8 mg;

    4: (4) Patients voluntarily participate in this study, sign a written informed consent form and are willing to cooperate with followup visits;

    5: (5) Patients are assessed by the investigator to have good compliance;

    6: (6) If both eyes meet the enrollment criteria, the study eye shall be selected according to the following rules: ① When the bestcorrected visual acuity (BCVA) of the two eyes is different, the eye with poorer visual acuity shall be selected; ② When the BCVA of the two eyes is the same, the right eye shall be selected by default.

Exclusion Criteria:

  • 1: (1) Insufficient quality of OCT images, which prevents reliable assessment of Central Retinal Thickness (CST) or Ellipsoid Zone (EZ);

    2: (2) Complete absence of the central EZ at baseline, making it impossible to evaluate its changes during followup;

    3: (3) Coexistence of other macular diseases that may interfere with the evaluation of macular structure (e.g., Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), etc.);

    4: (4) Any condition that may affect patient compliance or scheduled followup (e.g., severe mental disorders, cognitive impairment, substance abuse or addiction, etc.);

    5: (5) Participation in any other clinical research project, or having taken part in any drug clinical trial within 6 months prior to screening examinations;

    6: (6) Presence of any contraindications listed in the prescribing information for Aflibercept 8 mg;

    7: (7) Extraocular/periorbital or intraocular infection or inflammation in either eye at the time of the first study drug injection;

    8: (8) The fellow eye is receiving other intravitreal treatments other than Aflibercept;

    9: (9) The study eye has received intravitreal antiVEGF injections within the past 3 months, intravitreal glucocorticoid therapy within the past 3 months, or a dexamethasone intravitreal implant within the past 6 months;

    10: (10) The patient has a history of immunodeficiency diseases (e.g., HIV, etc.), cancer or malignant tumors, autoimmune diseases, severe cardiovascular or cerebrovascular diseases, or other illnesses that may significantly reduce life expectancy;

    11: (11) Pregnant or lactating women, or women of childbearing potential who are unwilling or unable to use effective contraceptive measures;

    12: (12) Known hypersensitivity to any ingredients contained in the study drug;

    13: (13) Patients deemed unsuitable for participation in this study by the investigator.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
他の:Aflibercept 8mg

Intravitreal Injection of Aflibercept 8 mg

Intravitreal Injection of Aflibercept 8 mg

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Fluctuation Index
時間枠:Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)

Parameter source: OCTcentral 1mm CST, including foveal retinal thickness and volume.Calculation formula: FI = Sum of absolute changes in CST between all adjacent visits from baseline to M12 ÷ Number of adjacent intervals.

Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)

二次結果の測定

結果測定
メジャーの説明
時間枠
BCVA
時間枠:Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)

After wearing corrective lenses, outcomes from the ETDRS 4-meter standard protocol or clinical results shall be uniformly converted to ETDRS letter scores; the same method, lighting and distance shall be maintained for the same subject throughout follow-up assessments.

Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月15日

一次修了 (推定)

2028年9月30日

研究の完了 (推定)

2028年9月30日

試験登録日

最初に提出

2026年11月4日

QC基準を満たした最初の提出物

2026年11月16日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • MR-44-26-077408

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する